Show simple item record

dc.contributor.authorGrande, Enrique
dc.contributor.authorDíaz, Ángel
dc.contributor.authorLópez, Carlos
dc.contributor.authorMunarriz, Javier
dc.contributor.authorReina, Juan José
dc.contributor.authorVera, Ruth
dc.contributor.authorBernárdez, Beatriz
dc.contributor.authorAller, Javier
dc.contributor.authorCapdevila, Jaume
dc.contributor.authorGarcía Carbonero, Rocío
dc.contributor.authorJiménez Fonseca, Paula
dc.contributor.authorTrapero Bertran, Marta
dc.identifier.citationGrande, Enrique; Díaz, Ángel; López, Carlos et al. «Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review». Therapeutic Advances in Endocrinology and Metabolism, 2019, vol 10. Disponible en: <>. Fecha de acceso: 21 ene. 2020. DOI: 10.1177/2042018819828217ca
dc.description.abstractBackground: Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. Compounding the issue is that data on resource utilization and cost-effectiveness of different diagnostic and therapeutic modalities for GEP-NETs are scarce. Methods: A systematic review on the economic impact of GEP-NETs was carried out using four databases: EMBASE, PubMed, the National Health Service Economic Evaluation Database and Cochrane review. Fully published articles from January 2000 to May 2017, in English and Spanish, were included. All articles that satisfied the inclusion criteria were included in the systematic review; summary descriptive statistics were used to describe the methodological characteristics. Results: The 14 studies selected included cost-of-illness analyses (n = 4), economic evaluations (n = 7) and budget impact analyses (n = 3). Almost all studies were performed in the United States. Healthcare costs for patients with NETs included medication, outpatient visits, hospitalizations, and check-ups/tests. Reducing adverse events is an area where cost savings could be achieved; however, there was not enough evidence on the cost impact of adverse events. Conclusion: There is a lack of data related to resource utilization in the field of GEP-NETs. Therefore, cost-effectiveness and budget impact studies of existing and emerging treatments are urgently needed to help the decision-making process for patients with
dc.publisherSAGE Publicationsca
dc.relation.ispartofTherapeutic Advances in Endocrinology and Metabolismca
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.subject.otherCost effectivenessca
dc.subject.otherGestió pressupostàriaca
dc.subject.otherBudget in businessca
dc.subject.otherControl presupuestarioca
dc.subject.otherServeis sanitarisca
dc.subject.otherServicios de saludca
dc.subject.otherHealth facilitiesca
dc.titleEconomics of gastroenteropancreatic neuroendocrine tumors: a systematic reviewca

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as